Novo, the drug-development company, partners with Anthropic to speed up drug discovery by using Anthropic’s Claude, according to multiple reports. The companies say the collaboration focuses on building targeted solutions and workflows intended to address challenges in the drug-discovery process.
The outlets describe the effort as aiming to improve parts of how research and development work progresses, rather than as a single clinical product launch. While the reports emphasize different aspects—one highlighting “drug discovery” and the other “drug development”—they converge on the central point: the partnership is designed to apply Claude to specific research workflows that could reduce time and effort in preclinical stages.
Neither outlet provides detailed technical specifications, performance results, or timelines in the provided excerpts. The reporting is also framed as a partnership to develop and integrate use cases, with the companies’ stated goal centered on accelerating discovery and development activities rather than commenting on regulatory or trial outcomes.
